AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02457234 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cultural immersion
Description: The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
Study NCT03252509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous radiologic gastrostomy
Description: Percutaneous radiologic gastrostomy: Under conscious sedation and local analgesia, the ultrasound is performed to determine abdominal structures. The stomach is distended using room air through a nasogastric catheter or a 5 French (Fr) catheter. Gastropexy is performed under fluoroscopic guidance. The stomach is accessed using a 18 gauge (G) needle. Guidewire is advanced to the stomach. Progressive tract dilatations until the size of the gastrostomy tube is achieved. The catheter is advanced through the peel-away sheath. The catheter's balloon is inflated with 10ml of distilled water. Iodine contrast is injected to confirm position. After the procedure, the patient is observed for 3 hours. If there are no complications, the patient is discharged.
Study NCT02685059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3).
Study NCT02685059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel 125 mg/m² weekly for 12 weeks
Study NCT02466594 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hilotherm Clinic®
Description: Controlled Thermoregulation using a water circulation based system (Hilotherm Clinic®). Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
Study NCT01137539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gynecare TVT-SECUR system
Description: All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence
Study NCT03410862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elderberry Extract
Description: Thick reddish-brown liquid of Sambucus Nigra (Black Elderberry)
Study NCT03410862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Thick reddish-brown liquid similar in appearance and taste to Elderberry Extract not containing elderberry
Study NCT03851939 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoinfusion (TAI) Combine Toripalimab
Description: Transarterial Chemoinfusion (TAI) Combine Toripalimab
Study NCT02377102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: 12 weeks of supervised physical therapy.
Study NCT03453892 — intervention group
Intervention type: DRUG
Intervention: Nivolumab
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.
Study NCT03453892 — intervention group
Intervention type: DRUG
Intervention: Pembrolizumab
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.
Study NCT03453892 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.
Study NCT03453892 — intervention group
Intervention type: DRUG
Intervention: Ipilimumab
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.
Study NCT03242655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HCV GET-Up (Group Evaluation and Treatment Uptake)
Description: Groups will meet for 4 weekly 1-hour sessions facilitated by the PI and focused on providing education, motivation, and behavior change skills, along with an HCV medical evaluation. Patients will then be offered HCV treatment by individual provider after 4-week group evaluation and education intervention.
Study NCT03780998 — intervention group
Intervention type: DRUG
Intervention: Life7
Description: Life7 will used on the perianal skin with finger tips
Study NCT02612909 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IVACFLU-A/H5N1 vaccine
Description: Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.
Study NCT02612909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVACFLU-A/H5N1 vaccine
Description: Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.
Study NCT02612909 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.
Study NCT03817671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 5% O2
Description: Culturing embryos in 5% O2 just after thawing and till embryo transfer
Study NCT03817671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% O2
Description: Culturing embryos in 2% O2 just after thawing and till embryo transfer
Study NCT01238003 — intervention group
Intervention type: OTHER
Intervention: Interpretation of blood test results
Description: Interpretation of blood test results
Study NCT02685059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin 90 mg/m² 2-weekly for 8 weeks
Study NCT02685059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
Study NCT01879644 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NF
Study NCT01879644 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SM
Study NCT01879644 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PE
Study NCT01879644 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SU
Study NCT01797406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum
Study NCT01797406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water injection
Description: Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
Study NCT00382642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron + Cognitive Behavioral Therapy
Description: 13 week outpatient trial
Study NCT00382642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Cognitive Behavioral Therapy
Description: 13 week outpatient trial
Study NCT01819285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Orchiectomy or depot LHRH
Study NCT01819285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Orchiectomy or depot LHRH
Study NCT05537870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cancer nurse navigator care
Description: oncology case manager care combined with cancer nurse navigator care
Study NCT05537870 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: case manager care
Description: case manager care (usual care)
Study NCT00622271 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group Therapy
Description: Self-management Group Protocol: The parent sessions will be structured by general topic area, but teaching of clinical and behavioral information will be derived from questions and problems posed by the group in order to actively meet the needs and concerns of participants. The parent sessions will be an interactive process of eliciting concerns and questions, presenting information to address those questions, and following up with a discussion to review concerns and strategies to address the behavioral aspects of the issues. The child sessions will be activity focused, with hands-on opportunities to practice the skills being taught.
Study NCT00940472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMMET-01
Description: 90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
Study NCT00940472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: 90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)
Study NCT04571528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + multicomponent treatment VIRTUAL FIBROWALK
Description: Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.
Study NCT04571528 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
Study NCT04571528 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU + Physiotherapy part of VIRTUAL FIBROWALK
Description: Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients: - Pain neuroscience education (30 min.) - Physical exercise(30 min.) - Treatment as Usual (TAU). Standard pharmacological treatment usually provided to patients with fibromyalgia.
Study NCT00838149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: Glutamine group :~Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
Study NCT01336361 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: A one-time paper survey was mailed to subjects, along with a cover letter, explanation of the research study, and contact and informed consent information. A reminder postcard was sent to subjects approximately one week later, encouraging return of the completed survey.
Study NCT02607748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-NaF PET and coronary CTA imaging
Study NCT02939131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm
Description: Behavioral therapy based on a manualized approach developed specifically for youth living with both HIV and depression, using problem-solving, motivational interviewing and cognitive-behavioral strategies to decrease adherence obstacles and increase wellness. The medication management algorithm includes guidance for clinicians on strategies and tactics to treat depression in this population, including factors to consider when deciding on treatments (i.e., drug-drug interactions, side effects).
Study NCT02939131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Ongoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training on current principles for use of medication and psychotherapy in the treatment of depression.
Study NCT03163602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Access flap and debridement
Study NCT03163602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test group
Description: Regenerative treatment
Study NCT02185976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cartoon
Description: 5 different cartoons which will be recorded on a tablet PC.
Study NCT03995719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative education
Description: 65 patients were instructed to a preoperative stoma-education program
Study NCT03257709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic acetabular labral repair
Description: Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
Study NCT03257709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic acetabular labral resection
Description: The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
Study NCT02122783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADR™ brace resistance
Study NCT02122783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional brace resistance (using hard stops)
Description: Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs
Study NCT02783079 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Study NCT02783079 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBSR
Study NCT04570059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling on textured food introduction between 8 and 15 months
Description: Intervention program : Advice and tips on the why and how introducing textured food during complementary feeding are grouped in a booklet and provided to participants. Monthly counselling via phone call by a dietician (at 9, 10, 11,12, 13, 14 months) and two baskets containing food preparation utensils and commercial textured foods provided at 8 and 12 months.~Usual care : reflects the standard information provided within French national guidelines (PNNS). Two phone calls at 9 and 13 months. If questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS. Two gift boxes containing presents for the child of same financial value as those provided to intervention group, provided at 8 and 12 months.
Study NCT04570059 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling on textured food introduction between 8 and 15 months
Description: Intervention program : Advice and tips on the why and how introducing textured food during complementary feeding are grouped in a booklet and provided to participants. Monthly counselling via phone call by a dietician (at 9, 10, 11,12, 13, 14 months) and two baskets containing food preparation utensils and commercial textured foods provided at 8 and 12 months.~Usual care : reflects the standard information provided within French national guidelines (PNNS). Two phone calls at 9 and 13 months. If questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS. Two gift boxes containing presents for the child of same financial value as those provided to intervention group, provided at 8 and 12 months.
Study NCT04440605 — intervention group
Intervention type: PROCEDURE
Intervention: Preoperative staging--D2 gastrectomy--Postoperative staging
Description: Preoperative TNM staging under CT scan plus endoscopy endoscopic biopsy, and postoperative staging after D2 gastrectomy
Study NCT03995719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative education
Description: 73 patients, receiving the same information in postoperative period.
Study NCT01286584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication
Study NCT01286584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
Study NCT00338182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1152 part A
Description: 48-hour continuous intravenous infusion
Study NCT00338182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1152 part B
Description: 2-hour intravenous infusion
Study NCT01873521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Study NCT04286997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRAIL population
Description: each subjects included in the intervention group will receive 20 GRAIL sessions, aimed to the walking pattern improvement, associated with 20 traditional physiotherapy sessions, aimed to the stabilization of the trained competences
Study NCT00840827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide 10mg po daily
Study NCT00840827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: CSA 250mg orally twice daily
Study NCT02319902 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard cold carbon dioxide gas
Description: Use of standard cold carbon dioxide gas in laparoscopic gynaecological surgery.
Study NCT02319902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated humidified carbon dioxide gas
Description: Use of the Fischer and Paykel heated humidification system for laparoscopic gynaecological surgery.
Study NCT04286997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GRAIL population
Description: each subjects included in the intervention group will receive 20 GRAIL sessions, aimed to the walking pattern improvement, associated with 20 traditional physiotherapy sessions, aimed to the stabilization of the trained competences
Study NCT00957125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.
Study NCT00957125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.
Study NCT00957125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
Study NCT01705067 — intervention group
Intervention type: DEVICE
Intervention: TKA with Journey II BCS Total Knee System
Description: TKA with Journey II BCS Total Knee System
Study NCT00653432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monovisc®
Description: Intra-articular injection
Study NCT00653432 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% Sterile Saline
Study NCT00005862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Study NCT03804671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Oral dose
Study NCT03804671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357 mixed with [C-14] BI 730357 BS
Description: Intravenous dose
Study NCT03742778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentivizing reflection
Description: Participants receive bonus incentives for reflecting on their workouts
Study NCT03742778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentivizing exercise
Description: Participants receive bonus incentives for exercising
Study NCT00891514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Treadmill training- begins at 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 45-60 minutes for 6 months
Study NCT00891514 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching, balance exercises, and components of conventional physical therapy-- begins at 15 minutes and progresses to 45 minutes for 6 months
Study NCT02408692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ECx1
Description: At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of \<25 kg/m2 will have completed study participation.